Sonidegib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Sonidegib. Educational only — not medical advice.
Labeled uses
ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Source: FDA labeling via NIH DailyMed (set 028312dc…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.